PET/CT used in study of Rexin-G for pancreatic cancer
SNM SmartBrief | 10/15/2008
PET/CT showed a decrease in metabolic activity in tumors in a clinical trial of Rexin-G for patients with pancreatic cancer. "I am happy with the positive results of Rexin-G seen in pancreatic cancer, and look forward to obtaining even better results with progressively higher doses of Rexin-G," said the principal investigator in a news release.
Earthtimes.org (04/21)